PT - JOURNAL ARTICLE AU - Nancy H. L. Leung AU - Samuel M. S. Cheng AU - Mario Martín-Sánchez AU - Niki Y. M. Au AU - Yvonne Y. Ng AU - Leo L. H. Luk AU - Karl C. K. Chan AU - John K. C. Li AU - Yonna W. Y. Leung AU - Leo C. H. Tsang AU - Sara Chaothai AU - Kelvin K. H. Kwan AU - Dennis K. M. Ip AU - Leo L. M. Poon AU - Gabriel M. Leung AU - J. S. Malik Peiris AU - Benjamin J. Cowling TI - BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine AID - 10.1101/2022.01.20.22269586 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.20.22269586 4099 - http://medrxiv.org/content/early/2022/01/21/2022.01.20.22269586.short 4100 - http://medrxiv.org/content/early/2022/01/21/2022.01.20.22269586.full AB - Limited data exist on antibody responses to mixed vaccination strategies involving inactivated COVID-19 vaccines, particularly in the context of emerging variants. We conducted an open label trial and administered a third vaccine dose of an mRNA vaccine (BNT162b2, BioNTech/Fosun Pharma) in adults aged ≥30 years who had previously received two doses of an inactivated COVID-19 vaccine. We collected blood samples prior to administering the third dose and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA), a surrogate virus neutralization test (sVNT) and a live virus plaque reduction neutralization test (PRNT), and to the Omicron variant using PRNT. A third dose of BNT162b2 substantially increased antibody titers on each assay. Mean ELISA levels increased from an optical density (OD) of 0.3 to 2.1 (p<0.01), and mean sVNT levels increased from an inhibition of 17% to 96% (p<0.01). In a random subset of 20 participants, the geometric mean PRNT50 titers rose very substantially by at least 27 fold from Day 0 to Day 28 against the ancestral virus (p<0.01) and rose by at least 14 fold against the Omicron variant (p<0.01). In daily monitoring, post-vaccination reactions subsided within 7 days for over 99% of participants. In conclusion, a third dose of COVID-19 vaccination with an mRNA vaccine substantially improved antibody levels against the ancestral virus and against the Omicron variant with well-tolerated safety profile, in adults who had received two doses of inactivated vaccine 6 months earlier.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.Clinical TrialNCT05057182Funding StatementThis project was supported by the Theme-based Research Scheme T11-712/19-N of the Research Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong West ClusterI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized raw data and R syntax to reproduce all the analyses, figures and tables in the published article will be made available after publication.